ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,066.00
-0.07%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,959.33
-0.18%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Enanta Pharmaceuticals Inc (ENTA)

  7. Enanta Pharmaceuticals Inc (ENTA) 뉴스

ENTA

Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ENTA
일자시간출처헤드라인심볼기업
2024/05/0905:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/05/0905:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/05/0720:00Business WireEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/05/0705:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/05/0705:01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/04/3020:10Business WireEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/04/3020:00Business WireEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/04/2920:00Business WireEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/04/1720:00Business WireEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0907:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/03/0621:00Business WireEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/2808:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/2803:11Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1510:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/1504:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/0914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/0906:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/0806:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTAEnanta Pharmaceuticals Inc
2024/02/0806:01Business WireEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ETNASDAQ:ENTAEnanta Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:ENTA

최근 히스토리

BIT
ABS
Arterra Bioscience
BIT
I07016
Intesa Sanpaolo
COIN
AG10UST
Agri10x Token
DGFX
PPIZZAUSDT
P Pizza
USOTC
FAXRF
Fairfax Financial (PK)
BIT
SNIO5S
Societe Generale Effekten
HITB
ETLUSDT
EtherLite
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유